Insys Therapeutics Inc (NASDAQ:INSY) closed Wednesday’s trading session at $5.95, and it has had a lot going on for the last few weeks including the announcement of data from its Epinephrine Nasal Spray Pharmacokinetic Study.
The company presented the initial Epinephrine Nasal Spray Pharmacokinetic study data at an annual conference held by the American Academy of Allergy, Asthma, and Immunology (AAAAI). The conference took place in San Francisco California on February 24 this year. Insys launched the Pharmacokinetic Study to evaluate its Epinephrine nasal spray’s safety and efficacy as a treatment for allergies.
The results presented at the AAAAI meeting were collected from the initial PK study which had 60 adult subjects that had seasonal allergies. The main goal of the study was to evaluate the bioavailability of two nasal formulations consisting of epinephrine and EpiPen 0.3 mg in patients with seasonal allergies but no allergen challenge.
The researchers in the study kept an eye out for adverse events, vital signs and they also carried out nasal exams, as well as ECG exams. The study results revealed that clinical subjects absorbed the two epinephrine nasal spray formulations rapidly and no allergen challenges were observed. The poster that Insys presented at the AAAAI event will be available for viewing on the company’s website.
“These results presented to the scientific community further support the potential for a needleless alternative to the current standard of care,” stated Insys’ Senior VP of research and development, Dr. Venkat Goskonda.
The intranasal delivery system is the ideal delivery system for the treatment
The Insys executive also noted that the results also validate the ability to deliver epinephrine as an allergic reaction treatment through an intranasal delivery system. This delivery system allows it to target allergic reactions such as anaphylaxis effectively. Goskonda also noted that the company looks forward to continued collaboration with the FDA towards bringing the developmental treatment to market.
Insys also supported the validity of the information provided on the Epinephrine nasal spray with data collected from its PK study which took place in January 2019. The company compared the pipeline treatment’s performance to the standard treatments targeting allergic reactions.